Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-11-21
2006-11-21
Nguyen, Quang (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S085400, C424S093200
Reexamination Certificate
active
07138379
ABSTRACT:
The present invention is directed towards a method of potentiating the anti-growth effects of type I interferon (IFN) on cells in a target cell population comprising increasing the number of functional IFNAR2c receptors on the surface of modified cells within the target cell population and then exposing the modified cells to a therapeutically effective amount of a type I IFN or by exposure to endogenously produced IFN.
REFERENCES:
patent: WO 96/18413 (1996-06-01), None
patent: WO 99/32141 (1999-07-01), None
patent: WO 99/47178 (1999-09-01), None
Xu et al. Clin. Cancer Res. 7:3314-3324, 2001.
Romano et al. Stem Cells 18:19-39, 2000.
Dang et al. Clin. Cancer Res. 5:471-474, 1999.
Verma et al. Nature 389:239-242, 1997.
Domanski et al. J. Biol. Chem. 273:3144-3147, 1998.
Lutfalla et al. EMBO J. 14:5100-5108, 1995.
Fish et al., Biochemical and Biophysical Research Communications, vol. 112, No. 2, Apr. 29, 1983, “Human Leukocyte Interferon Subtypes Have Different Antiproliferative And Antiviral Activities on Human Cells”.
Luis M. De La Maza, Infection and Immunity, Mar. 1985, vol. 47, No. 3, pp. 719-722, “Interferon-Induced Inhibition ofChlamydia trachomatis: Dissociation from Antiviral and Antiproliferative Effects”.
Aye-Aye Khine, J. Of Cellular Physiology (2000) vol. 182, pp. 97-108, “Functional Significance of Globotriaosyl Ceramide in Interferon ∂2/Type 1 Interferon Receptor-Mediated Antiviral Activity”.
Hiroomi Tada et al., The Journal of Clinical Investigation, Jul. 2001 vol. 108, No. 1, pp. 83-95, “Systemic IFN-β gene therapy results in long-term survival in mice with established colorectal liver metastases”.
Guangwen Cao et al., Cancer Gene Therapy, vol. 8 No. 7 (2001), pp. 497-505, “Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude mice”.
Mandell R. et al., American Association for Cancer Research, vol. 38, Mar. 1, 1997 p. 381 XP002074718, “Gene Therapy of Cancer by Retroviral Transfer and Expression of the rat sodium.iodine symporter (NIS)”.
Kim, S.H. et al., An International Journal On Genes And Genomes, Sep. 1, 1997, vol. 196, No. 1-2 pp. 279-286 XP004126355, “Mammalian type I interferon receptors consists of two subunits”.
Russell-Harde Dean et al., Journal of Biological Chemistry, (1995) vol. 270, No. 44, pp. 26033-26036 XP002184662 “Reconstitution of a high affinity binding site for type I interferons”.
Pfeffer Lawerence M. et al., (1997), vol. 272, No. 17, pp. 11002-1105, XP002184663, “The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action”.
Croze Ed
Russell-Harde Dean
Vogel David
Berlex Inc.
Nguyen Quang
Schering Aktiengesellschaft
LandOfFree
Use of the interferon receptor 2c polypeptide chain to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the interferon receptor 2c polypeptide chain to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the interferon receptor 2c polypeptide chain to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683338